Novel therapeutic approach to skin diseases with protein-transduction technology
Project/Area Number |
20591316
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Dermatology
|
Research Institution | University of Yamanashi |
Principal Investigator |
SHIBAGAKI Naotaka University of Yamanashi, 大学院・医学工学総合研究部, 准教授 (40262662)
|
Project Period (FY) |
2008 – 2010
|
Project Status |
Completed (Fiscal Year 2010)
|
Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2010: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2009: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2008: ¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
|
Keywords | タンパク質細胞内導入 / 分子標的薬 / 癌免疫療法 / STAT3 / 阻害薬 / 癌ワクチン / STAT3阻害薬 / 皮膚腫瘍 / タンパク導入 / 分子標的療法 / 分指標的療法 |
Research Abstract |
Protein-transduction domains (PTDs) are short stretches of cationic amino acids that enable peptides, proteins, oligonucleotides, and other reagents to efficiently enter multiple cell types. Therefore, PTDs offer unique therapeutic opportunities for the treatment of many diseases, including skin cancer. Novel STAT3 inhibitor ; R9-GRIM19 significantly reduced STAT3-dependent transcription in vitro, and tumor growth in vivo.
|
Report
(4 results)
Research Products
(27 results)